When was Engrail Therapeutics founded?

Engrail Therapeutics was founded in 2019 and raised its 1st funding round within a year of its incorporation.

Where is Engrail Therapeutics located?

Engrail Therapeutics is headquartered in San Diego, United States.

How many employees does Engrail Therapeutics have?

As of Sep 30, 2026, the latest employee count at Engrail Therapeutics is 32.

Is Engrail Therapeutics a funded company?

Engrail Therapeutics is a funded company, having raised a total of $221M across 5 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Feb 15, 2019.

When was the latest funding round of Engrail Therapeutics?

Engrail Therapeutics' latest funding was a $***** Series B round on Mar 19, 2024, with participation from 9 investors.

Where does Engrail Therapeutics rank among its competitors?

Engrail Therapeutics ranks 800th amongst 2892 active competitors, of which 973 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Engrail Therapeutics?

Engrail Therapeutics' top competitors include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Engrail Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapeutic compounds to treat neurological diseases. The company has developed ENX-101, a sub-type selective GABA A modulator, that is used to target and modulate the GABA A protein.

Website: www.engrail.com/
Social
Email ID: *****@engrail.com

Key Metrics

Founded Year

2019

Location

San Diego, United States

Stage

Series B

Total Funding

$221M in 5 rounds

Latest Funding Round

Series B, Mar 19, 2024, $*****

Investors

Nan Fung Life Sciences & 10 more

Ranked

800^th among 2892 active competitors

Employee Count

32 as on Sep 30, 2026

Investment & Acquisitions

Neurocycle Therapeutics

Similar Companies

Jazz Pharmaceuticals & 589 more

View Engrail Therapeutics' full profile

Engrail Therapeutics is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Engrail Therapeutics, Inc. CIN: 84-2517846 , United States, Active	Jun 20, 2019	-	16 (As on Dec 31, 2023)	-

Engrail Therapeutics has raised a total funding of $221M over 5 rounds. Its first funding round was on Feb 15, 2019. Its latest funding round was a Series B round on Mar 19, 2024 for $*****. 9 investors participated in its latest round. Engrail Therapeutics has 11 institutional investors.

Here is the list of recent funding rounds of Engrail Therapeutics:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 19, 2024	2429133	Series B	4841073	8318693	3973076	1685238
Aug 03, 2021	5836845	Series A	1062805	3172510	2752920	5664264
Jun 18, 2020	3496106	Series A	4503837	7916975	Nan Fung Life Sciences	9571581

Access funding benchmarks and valuations. Sign up today!

View details of Engrail Therapeutics's funding rounds and investors

The founders of Engrail Therapeutics is Stephen Cunningham.

Here are the details of Engrail Therapeutics' key team members:

Stephen Cunningham: Co-Founder & Chief Development Officer of Engrail Therapeutics. They are also an angel investor in 1 startup.

View details of Engrail Therapeutics's Founder profiles and Board Members

Engrail Therapeutics' employee count trend

Engrail Therapeutics has 32 employees as of Sep 26. Here is Engrail Therapeutics's employee count trend over the years:

Employee count trend for Engrail Therapeutics

Uncover Engrail Therapeutics' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Engrail Therapeutics include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Engrail Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Biogen 1978, Cambridge (United States), Public	Developer of therapies for neurodegenerative and immunology disorders	$80M	Berkshire Hathaway, Digital Pharma Lab & 11 others	78/100
3rd	PTC Therapeutics 1998, South Plainfield (United States), Public	Developer of small molecule drugs for the treatment of rare diseases	$248M	HBM Healthcare Investments, Credit Suisse First Boston ... & 28 others	77/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
5th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
800th	Engrail Therapeutics 2019, San Diego (United States), Series B	Developer of therapeutic compounds to treat neurological diseases	$221M	RiverVest Venture Partners, Pivotal bioVenture Partners China ... & 9 others	45/100